The Jeddah-based firms are organizing a shared cooperation route for corporate, commercial and dispute-related matters, while the Saudi Legal Consultation Directory provides a separate English-language educational reference for clients researching Saudi law.

JEDDAH, Saudi Arabia — September 10, 2026 —

Saudi firms formalize a broader cooperation route

Al-Safwa Law Firm for Advocacy and Legal Consultations and BMS Legal for Law and Legal Consulting have formalized a cooperation framework designed to support corporate, commercial and litigation-related matters in Saudi Arabia. The arrangement is intended to make it easier to route client files to the appropriate legal specialization while preserving a clear division of professional responsibility.

Both firms operate from Jeddah and publish English-language information for companies, investors and individuals who need to understand how a Saudi legal matter moves from initial review to consultation, drafting, negotiation, litigation or enforcement. The cooperation is particularly relevant to files that involve more than one legal discipline or require additional capacity, coordinated document review or continuity when a matter develops from advisory work into a dispute.

Why cooperation matters in complex legal files

Corporate legal work rarely stays in a single category. A shareholder agreement can lead to a governance question. A contract review can reveal a payment or performance dispute. An employment issue can involve internal policies as well as litigation risk. A real-estate transaction can become an enforcement matter. The cooperation framework is designed around that reality rather than around a one-service model.

Under the approach, the first task is to identify the client’s legal objective and the current stage of the matter. The relevant team can then review documents, deadlines and jurisdiction before deciding whether the file is primarily advisory, transactional, contentious or enforcement-related.

Professional teams add depth to the arrangement

Al-Safwa publicly identifies a multidisciplinary team that includes licensed Saudi lawyer Hussain Alhudhali, who works on personal-status and family-enforcement matters, as well as legal professionals serving research and consultation functions. The firm’s published team structure is intended to make responsibility and areas of practice more visible to clients.

BMS Legal publicly identifies licensed lawyers Sunaitan Mohammed bin Hayef Al-Subaie and Bashar Ahmed Khalaf Al-Omari. Its English verification pages publish professional license details for both lawyers. BMS also organizes work by practice area, including corporate and contracts, commercial matters, litigation, employment, family, criminal, administrative, real-estate and governance-related work.

Corporate governance and compliance

One area where the cooperation can be particularly useful is governance and compliance. BMS publishes a dedicated corporate governance and compliance track supervised by Sunaitan Mohammed bin Hayef Al-Subaie, including work around internal policies, governance regulations, conduct, conflicts of interest and regulatory obligations. That capability complements broader corporate and dispute-related work when a company needs to correct an internal issue before it becomes contentious.

Litigation and legal procedure

Al-Safwa’s team structure includes work on litigation and enforcement-related matters, with case handling built around reviewing facts and documents before selecting the procedural route. In a coordinated file, this allows a matter that begins with corporate advice or contract review to be assessed again if negotiations fail and court action or enforcement becomes necessary.

A separate educational layer for clients researching Saudi law

The cooperation also recognizes that not every person searching for legal information is ready to retain counsel. Saudi Legal Consultation Directory provides English-language educational material explaining Saudi laws, procedures, legal templates, official references and frequently asked questions.

The directory clearly states that it is informational and educational in nature and does not provide binding legal advice or legal representation. That distinction is useful because it allows a client to build a preliminary understanding of terminology and procedure before a licensed lawyer reviews the specific facts and documents.

How a coordinated file may move in practice

A typical business matter may begin with an English-language inquiry from an investor or company manager. The initial review can identify the parties, contract, regulatory context and immediate deadline. If the issue is preventive, the work may focus on drafting, negotiation, governance or compliance. If there is already a dispute, the analysis shifts to evidence, jurisdiction, procedural deadlines and the available litigation or settlement routes.

The point of cooperation is not to create duplicate reviews. It is to make the handoff deliberate. When another specialization is needed, the receiving team should understand what has already been reviewed, which documents control the matter and what the client is trying to achieve.

English-language access for international businesses

Saudi Arabia continues to attract international companies, investors and professionals who often begin their legal research in English. Clear English pages can help them verify the official name of a legal entity, identify practice areas and understand whether a website is providing legal representation, educational information or another type of service.

That clarity is also important for corporate legal departments that need an auditable starting point before referring a matter to outside counsel. Entity names, locations, professional roles, license information and service descriptions are more useful than broad claims when a company is assessing who should handle a legal file.

About Al-Safwa Law Firm for Advocacy and Legal Consultations

Al-Safwa Law Firm for Advocacy and Legal Consultations is a Jeddah-based Saudi law firm providing legal consultation, advocacy and case support across a range of Saudi legal matters. Its English-language website identifies lawyers and legal team members and explains the firm’s approach to document review, legal planning and case follow-up.

About BMS Legal for Law and Legal Consulting

BMS Legal for Law and Legal Consulting is a professional legal company in Jeddah. Its public English pages identify the company and its licensed lawyers, including Sunaitan Mohammed bin Hayef Al-Subaie and Bashar Ahmed Khalaf Al-Omari, and provide verification information around professional licensing and Saudi Bar membership.

About Saudi Legal Consultation Directory

Saudi Legal Consultation Directory is an educational legal-information platform focused on simplified explanations of Saudi law, official references, practical guides, templates and FAQs. It states that its content is non-binding and does not replace case-specific advice from a licensed lawyer.

Cooperation with defined limits

The firms’ cooperation does not create a guarantee of outcome or replace the need for a formal engagement on a specific case. Every matter remains subject to its facts, documents, applicable Saudi laws, court or authority requirements and professional-conflict checks. The value of the arrangement is in capacity, specialization and clearer routing — not in overstating what a cooperation agreement can achieve.

Country: Saudi Arabia
Contact Person: Mustafa Ahmed Diab Mohammed
Website:https://hd-lawfirm.com.sa
Email: info@hd-lawfirm.com.sa

HALLANDALE BEACH, Fla. — September 2026 — Polar Monkeys, an industry-leading recovery and wellness equipment company based in Hallandale Beach, Florida, has announced the launch of its ONE cold plunge system and new residential sauna collection, expanding its premium product portfolio across both cold and heat based recovery equipment.

The ONE cold plunge is priced at $6,290 and is designed as a cooling-only system. According to Polar Monkeys, the unit uses a fully insulated acrylic tub and a 0.8-horsepower chiller rated at 10,577 BTUs. The company states that the system can reach water temperatures of 32°F and is designed to produce ice.

The ONE measures approximately 71 inches long, 31.5 inches wide and 23.5 inches high, with a stated 90-gallon capacity. The system is designed for use with a standard 110V household outlet and includes dual-stage water filtration, automatic sanitation and integrated WiFi controls through the Polar Monkeys mobile application.

The unique difference is that the ONE series offers a cost-effective yet premium solution designed for users who want cold-water use only. The company continues to offer other cold-plunge models, including the Brainpod 2.0, The Barrel collection, Cyber Plunge and Contrast Edition.

Alongside the ONE, Polar Monkeys has introduced a residential sauna collection consisting of the Baia Glass Sauna and Mira Natural Sauna. The Baia Glass Sauna is designed for indoor installation, while the Mira Natural Sauna is designed for outdoor use. According to the company, both models use thermally modified spruce exteriors, thermo-aspen interiors, full-glass fronts and WiFi-controlled Harvia Spirit heaters. Each model is available in two sizes.

The company has also announced a bundle combining a residential sauna with its Brainpod 2.0 cold plunge, giving customers the option to combine separate heat and cold systems.

Polar Monkeys’ expanded product range follows their recent recognition from industry leading publications for their products from publications including Men’s Health, Fortune and Garage Gym Reviews. Specific award categories and publication dates should be independently verified through the respective publications.

Polar Monkeys is headquartered at 237 Northwest 4th Avenue in Hallandale Beach, Florida. The company can be contacted at info@polarmonkeys.com.

About Polar Monkeys

Polar Monkeys is an industry-leading recovery and wellness equipment company specializing in premium cold-plunge, contrast-therapy, and sauna systems for residential and commercial environments. Headquartered in Florida, the company designs high-performance recovery solutions for homes, gyms, wellness centers, spas, hospitality properties, professional sports organizations, and other high-use facilities. Its product portfolio combines advanced temperature control, premium materials, certified components, and purpose-built residential and commercial engineering to deliver reliable cold, heat, and contrast therapy experiences.

Media Details

Company Name: Polar Monkeys
Country: United States
Contact Person: Eric Halfen
Email: info@polarmonkeys.com

MELBOURNE, Victoria, Australia — September 10, 2026 — Cullen Jewellery is highlighting the growing role of lab-grown diamonds in the engagement ring market as consumers increasingly consider sourcing, pricing and customization when selecting jewelry.

Lab-grown diamonds have become a more established option for engagement rings in recent years. Produced using technology that recreates the conditions required to form diamonds, laboratory-grown stones have essentially the same chemical composition and crystal structure as mined diamonds. Their availability has also contributed to broader consumer discussion around alternative sourcing and jewelry purchasing decisions.

Price remains one factor influencing interest in lab-grown diamonds. Depending on the stone’s characteristics and market conditions, laboratory-grown diamonds can be substantially less expensive than comparable mined diamonds. The difference can allow buyers to allocate more of their budget toward the center stone’s cut, the setting, or other elements of a custom ring.

Environmental considerations are also part of the discussion. While laboratory production requires energy and therefore has its own environmental considerations, lab-grown diamonds do not require the extraction of diamond-bearing material from the ground. Cullen Jewellery has incorporated lab-grown diamonds into its sourcing approach as part of its focus on providing customers with alternative options for engagement ring purchases.

“Consumers are asking more detailed questions about where their jewelry comes from and how it is made,” said a Cullen Jewellery representative. “For many couples, the ability to select a lab-grown diamond and customize the surrounding setting provides greater flexibility when creating an engagement ring that reflects their individual preferences.”

Customization is another area where lab-grown diamonds can influence the purchasing process. Because the cost of the center stone can represent a smaller portion of the overall budget, buyers may have additional flexibility when considering bespoke settings and design details.

Cullen Jewellery works with customers on custom engagement ring designs, allowing the setting to be developed around the selected stone, preferred style and individual requirements. The approach is intended to give customers greater involvement in the design process rather than limiting them to standardized settings.

Consumers considering a lab-grown diamond can also request independent grading documentation and review the specifications of the individual stone. Organizations such as the International Gemological Institute (IGI) and the Gemological Institute of America (GIA) provide diamond-grading services, giving buyers an additional source of information when comparing stones.

The construction of the ring setting is another consideration. Buyers may wish to ask whether a setting is cast or fabricated, what maintenance may be required over time, and whether the design can accommodate future resizing or repairs.

As lab-grown diamonds become a more established part of the jewelry market, purchasing decisions are increasingly influenced by a combination of price, sourcing, design flexibility and long-term considerations. Cullen Jewellery continues to offer lab-grown diamond engagement rings and custom design options for consumers exploring these alternatives.

About Cullen Jewellery

Cullen Jewellery is an Australian jewelry company specializing in lab-grown diamond engagement rings, wedding rings and custom jewelry. The company works with customers to develop personalized designs and provides lab-grown diamond options for engagement and fine jewelry purchases.

Media Contact

Company Name: Cullen Jewellery
Contact Person: Media Relations
Email: sales@cullenjewellery.com
Website: cullenjewellery.com

Toronto, Canada — September 10, 2026 — Foreign businesses planning to establish operations in Canada are increasingly required to consider corporate structure, tax filing, accounting, governance, indirect taxes and cross-border transactions before beginning significant commercial activity, according to an industry-focused review of Canadian market-entry requirements.

The review highlights that entering the Canadian market is not necessarily limited to incorporating a Canadian subsidiary. Depending on the nature and location of business activities, a foreign corporation may have Canadian filing or tax obligations even when it does not establish a separate Canadian corporation.

Early consideration of the operating structure can therefore help international businesses identify potential compliance requirements before contracts, employees, financing arrangements and related-party transactions are established.

Corporate Structure Can Affect Compliance

Foreign investors considering Canada may evaluate whether to operate through an existing foreign corporation or establish a Canadian subsidiary. The appropriate structure can depend on commercial objectives, liability considerations, Canadian taxation, applicable tax treaties, permanent-establishment considerations and the intended movement of profits and funds between jurisdictions.

Investors should also consider the jurisdiction in which a Canadian corporation is established. Federal, provincial and territorial corporate legislation can impose different governance requirements, including rules concerning directors.

The applicable requirements should be reviewed before a corporate structure is finalized rather than after Canadian operations have already begun.

Tax Filing and GST/HST Requirements

Canadian tax compliance can extend beyond incorporation. Canadian-resident corporations generally have annual corporate income-tax filing obligations, while non-resident corporations carrying on business in Canada may also have Canadian filing obligations depending on their circumstances.

GST/HST represents a separate compliance system. Businesses should determine whether their activities require registration and understand the associated collection, record-keeping, filing and remittance responsibilities.

Businesses employing Canadian workers may also need procedures for payroll deductions, remittances, records and information reporting.

Cross-Border Transactions Require Additional Planning

International ownership can introduce additional considerations when Canadian operations transact with foreign parent companies, affiliates or other related parties.

Payments such as dividends, interest, royalties and certain service or management fees may have Canadian withholding-tax implications. Applicable tax treaties can affect the treatment of qualifying transactions.

Transfer pricing can also become relevant when applicable cross-border transactions take place between non-arm’s-length parties. Transactions involving services, financing, intellectual property, management fees or the purchase and sale of goods may require appropriate analysis and documentation.

These issues can be more efficiently addressed when identified during the planning stage rather than after transactions have accumulated.

Accounting and Record-Keeping Remain Fundamental

Accurate bookkeeping provides the foundation for corporate tax reporting and ongoing compliance. Canadian businesses with international ownership may need records that clearly distinguish revenue, expenses, assets, liabilities, payroll, GST/HST, shareholder funding, intercompany loans and related-party transactions.

Maintaining records throughout the year can reduce the need for extensive reconstruction during tax-filing periods and can help businesses identify potential compliance issues earlier.

Cost Should Be Evaluated Alongside Scope

Professional service costs can vary significantly according to transaction volume, employee numbers, filing history, international activity and the complexity of a company’s structure.

Businesses comparing accounting, tax or governance services should therefore evaluate the scope of work included in a quoted or advertised starting price rather than relying solely on the lowest headline fee.

For international businesses, the overall cost of Canadian compliance may include recurring accounting and tax work as well as specialist advice relating to cross-border transactions, corporate governance, tax treaties, permanent-establishment exposure and transfer pricing.

Planning Before Expansion

The review recommends that foreign investors consider Canadian tax and corporate compliance as an integrated part of their market-entry strategy.

Before launching significant Canadian operations, businesses can assess:

• Their proposed Canadian operating structure;
• Applicable corporate and tax filing obligations;
• GST/HST registration requirements;
• Payroll responsibilities;
• Corporate governance requirements;
• Potential permanent-establishment exposure;
• Payments to foreign shareholders or related entities;
• Transfer-pricing considerations; and
• Record-keeping and compliance procedures.

A structured assessment at the beginning of the expansion process can provide greater visibility into recurring obligations and help businesses avoid compliance issues caused by decisions made before the Canadian operation is fully established.

About the Review

This industry review examines common tax, accounting and corporate-compliance considerations relevant to international businesses evaluating expansion into Canada. Regulatory and tax requirements can vary according to the facts of each business and the applicable federal, provincial, territorial and treaty framework.

Businesses should obtain professional advice based on their specific circumstances before making corporate, tax or investment decisions.

Media Contact

Udit Gupta
Taxccount
Website: https://taxccount.com/
Email: udit@taxccount.com

Lenzburg, Switzerland — Dr.-Ing. Hans Michael Kellner, Managing Director of Messer Schweiz AG, will take on a new role as Chief Marketing Officer of the Messer Group beginning in October 2026, expanding his responsibilities from the Swiss organization to the strategic growth of the internationally operating group.

With about four decades of experience in the industrial gases sector, Dr. Kellner brings an engineering background, commercial experience, and extensive leadership expertise to his expanded responsibilities. His career has focused on industrial gases, hydrogen technologies, sustainable development, and the practical application of new technologies.

In his new position, Dr. Kellner will contribute to the strategic growth of the Messer Group and support the wider implementation of new technologies and innovations across its international operations.

A Career Built on Engineering and Industrial Experience

Dr. Kellner’s professional journey combines engineering expertise with commercial and executive leadership.

After developing an early interest in industrial technology, he pursued engineering studies with a focus on energy and process engineering before building his career in the industrial gases sector.

Over the course of his professional career, he has worked across technical, commercial, and management functions, developing experience in areas ranging from process engineering and specialty gases to hydrogen applications and sustainable industrial technologies.

His leadership approach has been shaped by the view that technological development must be supported by practical implementation, commercial discipline, and long-term planning.

Leading Messer Schweiz AG

As Managing Director of Messer Schweiz AG, Dr. Kellner has been responsible for the company’s Swiss operations and its activities across a range of industrial and commercial sectors.

During his more than two decades of leadership, Messer Schweiz has expanded its business while maintaining a stable workforce. The organization has also continued to develop technologies focused on hydrogen, energy efficiency, and sustainable industrial applications.

The industrial gases sector supports a wide range of industries, including manufacturing, healthcare, food and beverages, electronics, energy, and advanced technologies. As these industries respond to changing energy and environmental requirements, the sector is experiencing significant technological development.

Hydrogen and Industrial Innovation

Hydrogen has been an important area of Dr. Kellner’s professional work for many years.

Messer Schweiz has been involved in several hydrogen-related developments, including the supply of hydrogen for early fuel-cell applications and the development of hydrogen filling infrastructure.

One of the notable developments associated with the organization was the use of metal hydride technology for hydrogen compression. The technology enables hydrogen to be compressed to high pressures without conventional electrically driven compression systems.

Messer Schweiz also developed an industrial hydrogen compressor capable of reaching pressures of up to 700 bar without moving components or direct electrical power consumption for the compression process.

These developments reflect Dr. Kellner’s approach to engineering: identifying technologies that can address practical industrial requirements while considering efficiency, scalability, and long-term sustainability.

Innovation and Sustainable Development

A central element of Dr. Kellner’s professional philosophy is what he describes as “economic environmental protection.”

The approach focuses on developing sustainable and energy-efficient solutions that can also remain economically viable.

For industrial companies, he believes environmental progress needs to be considered together with competitiveness, infrastructure requirements, and long-term economic realities.

The transition toward hydrogen and other alternative energy technologies presents opportunities across transportation, manufacturing, energy, and other industrial sectors. At the same time, successful implementation requires infrastructure, investment, technical expertise, and cooperation between industry stakeholders.

The Human Side of Industrial Leadership

Technology is only one part of Dr. Kellner’s leadership approach.

Throughout his career, he has emphasized the importance of employee engagement, professional development, collaboration, and creating an environment where employees can contribute ideas.

At Messer Schweiz, this philosophy has included initiatives designed to encourage communication across organizational levels and support professional development.

Dr. Kellner considers the ability to bring together different perspectives an important component of innovation, particularly in industries where complex technical and commercial challenges require multidisciplinary solutions.

A New Chapter for Global Growth

With his transition to the role of Chief Marketing Officer of the Messer Group in October 2026, Dr. Kellner will bring his experience in industrial gases, engineering, technology development, and business leadership to a broader international mandate.

The new responsibility comes at a period of significant change across the industrial and energy sectors, with hydrogen, decarbonization, energy efficiency, and alternative technologies continuing to influence investment and business strategies.

In his expanded role, Dr. Kellner expects to contribute to the faster implementation of new technologies across the Messer Group and support the international development of emerging sustainable solutions.

“The possibilities to improve something with gases seemed limitless to me when I started my career. I continue to see the same potential today, particularly when technology, sustainability and practical industrial application come together,” said Dr. Kellner.

Looking Ahead

The coming years are expected to bring continued changes to the industrial gases and energy sectors. The development of hydrogen infrastructure, alternative energy solutions, and more efficient industrial processes will require both technological development and strategic implementation.

For Dr. Hans Michael Kellner, the next chapter will build on four decades of engineering and industrial experience while expanding his focus to the strategic growth of the Messer Group internationally.

His professional journey from engineering and process technology to executive leadership and hydrogen innovation continues to evolve as the industrial sector moves toward new technologies and sustainable solutions.

Media Contact

Dr. Hans Michael Kellner
Managing Director & CEO – Messer Schweiz AG
President – Swiss Industrial Gases Association
Vice-President – Hydropole
LinkedIn: https://www.linkedin.com/in/dr-hans-michael-kellner-a7948ab7
Website: https://www.messer.ch
Email: Hans-Michael.Kellner@messergroup.com

New formulation provides patients with a simplified dosing experience—reducing pill burden and enhancing ease of administration—while preserving flexible dosing options

SAN CARLOS, Calif.– BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved a new tablet formulation of BRUKINSA^® (zanubrutinib) for all five approved indications. BRUKINSA remains the leader in new chronic lymphocytic leukemia (CLL) patient starts across all lines of therapy in the U.S., and for the first time, has become the overall BTK inhibitor market share leader.¹

BRUKINSA tablets have the same efficacy and safety as BRUKINSA capsules based on the results of two single-dose, open-label, randomized Phase 1 crossover studies of healthy adults designed to establish bioequivalence. BRUKINSA is the only BTK inhibitor to offer the flexibility of once or twice daily dosing, with the ability to tailor the schedule to patient needs. It also continues to be the only BTK inhibitor with recommended dosing for severe hepatic impairment.

“BRUKINSA’s leadership in the U.S. underscores the trust physicians and patients have placed in its differentiated clinical profile,” said Matt Shaulis, General Manager of North America, BeOne. “With this new tablet formulation, we are making treatment simpler and more convenient—an important step forward for patients facing certain B-cell cancers.”

The recommended dose of BRUKINSA remains at 320 mg daily. The new BRUKINSA FDA approval tablets are 160 mg each, allowing patients to take two tablets daily rather than four of the current 80 mg capsules. Additionally, BRUKINSA tablets are smaller than the capsules and have a film coating, making them easier to swallow. The BRUKINSA tablets will replace capsules starting in October 2025.

The European Medicines Agency is currently reviewing a Type II variation marketing authorization application (MAA) for the new tablet formulation of BRUKINSA in all currently approved indications, with approval expected later this year.

About BRUKINSA^® (zanubrutinib)

BRUKINSA is an orally available, small molecule inhibitor of Bruton’s tyrosine kinase (BTK) designed to deliver complete and sustained inhibition of the BTK protein by optimizing bioavailability, half-life, and selectivity. With differentiated pharmacokinetics compared with other approved BTK inhibitors, BRUKINSA has been demonstrated to inhibit the proliferation of malignant B cells within a number of disease-relevant tissues.

BRUKINSA has the broadest label globally of any BTK inhibitor and is the only BTK inhibitor to provide the flexibility of once or twice daily dosing. Additionally, BRUKINSA is also the only BTK inhibitor to demonstrate superiority to another BTK inhibitor in a Phase 3 study.

The global BRUKINSA clinical development program includes about 7,100 patients enrolled in 30 countries and regions across more than 35 trials. BRUKINSA is approved in more than 75 markets in at least one indication, and more than 200,000 patients have been treated globally.

U.S. Indications and Important Safety Information for BRUKINSA (zanubrutinib)

INDICATIONS

BRUKINSA is a kinase inhibitor indicated for the treatment of adult patients with:

• Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
• Waldenström’s macroglobulinemia (WM).
• Mantle cell lymphoma (MCL) who have received at least one prior therapy.
• Relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen.
• Relapsed or refractory follicular lymphoma (FL), in combination with obinutuzumab, after two or more lines of systemic therapy.

The MCL, MZL and FL indications are approved under accelerated approval based on overall response rate and durability of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

Hemorrhage

Fatal and serious hemorrhage has occurred in patients with hematological malignancies treated with BRUKINSA. Grade 3 or higher hemorrhage including intracranial and gastrointestinal hemorrhage, hematuria, and hemothorax was reported in 3.8% of patients treated with BRUKINSA in clinical trials, with fatalities occurring in 0.2% of patients. Bleeding of any grade, excluding purpura and petechiae, occurred in 32% of patients.

Bleeding has occurred in patients with and without concomitant antiplatelet or anticoagulation therapy. Coadministration of BRUKINSA with antiplatelet or anticoagulant medications may further increase the risk of hemorrhage.

Monitor for signs and symptoms of bleeding. Discontinue BRUKINSA if intracranial hemorrhage of any grade occurs. Consider the benefit-risk of withholding BRUKINSA for 3-7 days before and after surgery depending upon the type of surgery and the risk of bleeding.

Infections

Fatal and serious infections (including bacterial, viral, or fungal infections) and opportunistic infections have occurred in patients with hematological malignancies treated with BRUKINSA. Grade 3 or higher infections occurred in 26% of patients, most commonly pneumonia (7.9%), with fatal infections occurring in 3.2% of patients. Infections due to hepatitis B virus (HBV) reactivation have occurred.

Consider prophylaxis for herpes simplex virus, pneumocystis jirovecii pneumonia, and other infections according to standard of care in patients who are at increased risk for infections. Monitor and evaluate patients for fever or other signs and symptoms of infection and treat appropriately.

Cytopenias

Grade 3 or 4 cytopenias, including neutropenia (21%), thrombocytopenia (8%) and anemia (8%) based on laboratory measurements, developed in patients treated with BRUKINSA. Grade 4 neutropenia occurred in 10% of patients, and Grade 4 thrombocytopenia occurred in 2.5% of patients.

Monitor complete blood counts regularly during treatment and interrupt treatment, reduce the dose, or discontinue treatment as warranted. Treat using growth factor or transfusions, as needed.

Second Primary Malignancies

Second primary malignancies, including non-skin carcinoma, have occurred in 14% of patients treated with BRUKINSA. The most frequent second primary malignancy was non-melanoma skin cancers (8%), followed by other solid tumors in 7% of the patients (including melanoma in 1% of patients) and hematologic malignancies (0.7%). Advise patients to use sun protection and monitor patients for the development of second primary malignancies.

Cardiac Arrhythmias

Serious cardiac arrhythmias have occurred in patients treated with BRUKINSA. Atrial fibrillation and atrial flutter were reported in 4.4% patients treated with BRUKINSA, including Grade 3 or higher cases in 1.9% of patients. Patients with cardiac risk factors, hypertension, and acute infections may be at increased risk. Grade 3 or higher ventricular arrhythmias were reported in 0.3% of patients.

Monitor for signs and symptoms of cardiac arrhythmias (e.g., palpitations, dizziness, syncope, dyspnea, chest discomfort), manage appropriately, and consider the risks and benefits of continued BRUKINSA treatment.

Hepatotoxicity, Including Drug-Induced Liver Injury

Hepatotoxicity, including severe, life-threatening, and potentially fatal cases of drug-induced liver injury (DILI), has occurred in patients treated with Bruton tyrosine kinase inhibitors, including BRUKINSA.

Evaluate bilirubin and transaminases at baseline and throughout treatment with BRUKINSA. For patients who develop abnormal liver tests after BRUKINSA, monitor more frequently for liver test abnormalities and clinical signs and symptoms of hepatic toxicity. If DILI is suspected, withhold BRUKINSA. Upon confirmation of DILI, discontinue BRUKINSA.

Embryo-Fetal Toxicity

Based on findings in animals, BRUKINSA can cause fetal harm when administered to a pregnant woman. Administration of zanubrutinib to pregnant rats during the period of organogenesis caused embryo-fetal toxicity, including malformations at exposures that were 5 times higher than those reported in patients at the recommended dose of 160 mg twice daily. Advise women to avoid becoming pregnant while taking BRUKINSA and for 1 week after the last dose. Advise men to avoid fathering a child during treatment and for 1 week after the last dose. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus.

Adverse Reactions

The most common adverse reactions (≥30%), including laboratory abnormalities, in patients who received BRUKINSA (N=1729) are decreased neutrophil count (51%), decreased platelet count (41%), upper respiratory tract infection (38%), hemorrhage (32%), and musculoskeletal pain (31%).

Drug Interactions

CYP3A Inhibitors: When BRUKINSA is co-administered with a strong CYP3A inhibitor, reduce BRUKINSA dose to 80 mg once daily. For coadministration with a moderate CYP3A inhibitor, reduce BRUKINSA dose to 80 mg twice daily.

CYP3A Inducers: Avoid coadministration with strong or moderate CYP3A inducers. Dose adjustment may be recommended with moderate CYP3A inducers.

Specific Populations

Hepatic Impairment: The recommended dose of BRUKINSA for patients with severe hepatic impairment is 80 mg orally twice daily.

Please see full U.S. Prescribing Information including U.S. Patient Information.

This information is intended for a global audience. Product indications vary by region.

About BeOne

BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of more than 11,000 colleagues spanning six continents, the Company is committed to radically improving access to medicines for far more patients who need them.

To learn more about BeOne, please visit www.beonemedicines.com and follow us on LinkedIn, X, Facebook and Instagram.

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding physicians and patients trust in BRUKINSA; whether the new tablet formulation for BRUKINSA will result in better patient experience; and BeOne’s plans, commitments, aspirations, and goals under the heading “About BeOne.” Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne’s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing, and progress of clinical trials and marketing approval; BeOne’s ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne’s ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne’s reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeOne’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products and its ability to obtain additional funding for operations and to complete the development of its drug candidates and maintain profitability; and those risks more fully discussed in the section entitled “Risk Factors” in BeOne’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeOne’s subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeOne undertakes no duty to update such information unless required by law.

To access BeOne media resources, please visit our News & Media site.

ANAHEIM, CA — September 9, 2026 — Indian ethnic fashion brand Dhiyona today announced the expansion of its international customer access through a strategic partnership with Indyancart, an e-commerce platform focused on connecting global consumers with Indian brands and products.

The collaboration is designed to make Dhiyona’s Indian ethnic wear collections more accessible to customers in the United States, United Kingdom, Canada, Australia, New Zealand, Japan, Singapore, South Korea, and other international markets.

Through the partnership, international customers can access Dhiyona’s collections through cross-border e-commerce and delivery infrastructure, with checkout and billing options available in local currencies where supported.

Based in Hyderabad, India, Dhiyona works with a manufacturing ecosystem across key Indian textile hubs. The company states that its network includes more than 400 manufacturing units supporting the sourcing, production, and distribution of its ethnic fashion collections.

Dhiyona’s product range includes sarees, festive wear, traditional ethnic ensembles, and customized fashion options. The brand’s international strategy focuses on serving Indian-origin communities and other consumers seeking access to Indian fashion for festivals, weddings, family celebrations, and cultural occasions.

“Indian communities around the world continue to look for convenient ways to access authentic products that help them stay connected with their cultural traditions,” said a spokesperson for Dhiyona. “Our collaboration with Indyancart is intended to simplify the international shopping experience while expanding access to Indian ethnic fashion beyond domestic markets.”

In addition to ready-to-wear collections, Dhiyona offers customization options that allow customers to personalize selected aspects of fit, fabric, and design. The company also operates a “Build Your Own Boutique” model designed to provide aspiring entrepreneurs with an opportunity to establish fashion businesses without maintaining traditional inventory.

Indyancart supports international ordering and cross-border logistics for Indian products, serving as a digital and logistical platform connecting international consumers with Indian brands. Through the collaboration, Dhiyona customers can access international checkout and direct-to-door delivery services across supported markets.

Dhiyona said the partnership reflects growing international demand for Indian ethnic fashion and products that connect global consumers with Indian craftsmanship and cultural traditions.

The company reports that it has served more than 50,000 customers and provides worldwide delivery, with typical delivery timelines of approximately 7 to 10 days depending on destination, shipping conditions, and product availability.

About Dhiyona

Dhiyona is a Hyderabad-based Indian fashion brand focused on ethnic, festive, and traditional wear. The company works with manufacturing partners across India’s textile ecosystem and serves customers in India and international markets. Its collections include sarees, ethnic ensembles, customized fashion options, and products designed for cultural celebrations and special occasions.

Media Contact

Dhiyona
United States: 1724 S Angel Ct, Anaheim, CA 92802
Email: Ceo@dhiyona.com

HOUSTON, Texas — September 9, 2026 — Rescue French Bulldogs, a Houston-based 501(c)(3) nonprofit organization incorporated in Texas in 2020, is highlighting its continued work rescuing, rehabilitating and placing French Bulldogs through a foster-based network serving the United States and Canada.

The organization says its work focuses on French Bulldogs requiring different forms of care, including dogs surrendered by owners or entering rescue from shelters. According to information published by Rescue French Bulldogs, the organization has rescued more than 100 French Bulldogs since 2020 through a network of foster families.

“Since we started in 2020, we have worked to develop a rescue model that addresses the particular needs of French Bulldogs,” said Linh Hoang, founder of Rescue French Bulldogs. “Our foster families, veterinary partners, adopters and supporters have each played an important role in helping these dogs move toward permanent homes.”

Addressing Breed-Specific Rescue Needs

French Bulldogs are a brachycephalic breed and may require specialized veterinary attention and individualized care. Rescue organizations can encounter dogs requiring treatment or additional monitoring following surrender, shelter intake or other circumstances.

Rescue French Bulldogs operates through a foster-based model in which dogs receive care in private homes while their medical, behavioral and placement needs are assessed. The organization’s website says its foster network supports dogs through veterinary care, food, grooming and other services associated with the rescue and rehoming process.

Individual care plans vary according to each dog’s circumstances. The organization says its adoption process is designed to consider the compatibility between a dog and prospective adopter before placement.

Rescue Experience and FrenchieGPT

Rescue French Bulldogs has also been involved in the development of FrenchieGPT, an AI application designed to provide information and guidance relating to French Bulldogs and dogs.

The application is associated with Linh Hoang and is listed on Apple’s App Store, where Rescue French Bulldogs is identified as the seller.

The organization describes FrenchieGPT as an educational resource informed in part by experience gained through its rescue activities. The application is not presented as a replacement for veterinary care, and owners should consult qualified veterinary professionals for diagnosis and treatment of medical conditions.

“Every dog we rescue contributes to our understanding of the breed,” Hoang said. “That experience has helped inform the educational resources we are developing for French Bulldog owners.”

Adoption, Foster and Support Information

Families interested in adopt a french bulldog can review the organization’s adoption information and application requirements through its website. Rescue French Bulldogs says prospective adopters are evaluated based on their circumstances and the needs of individual dogs.

Individuals interested in fostering or supporting the organization’s work can also find information through the organization’s website. Information regarding french bulldog rescue and surrender procedures is available online.

About Rescue French Bulldogs

Rescue French Bulldogs is a Houston-based 501(c)(3) nonprofit organization incorporated in Texas in 2020 and identified by EIN 84-4704649. Independent nonprofit records identify the organization as an animal-protection and welfare organization.

The organization operates a foster-based rescue network focused on rescuing, rehabilitating and rehoming French Bulldogs in the United States and Canada. Rescue French Bulldogs also identifies itself as a rescue partner of FrenchBulldog.com and has been involved in the development of FrenchieGPT.

For more information, visit rescuefrenchbulldogs.org.

Media Contact:

Rescue French Bulldogs
info@rescuefrenchbulldogs.org
rescuefrenchbulldogs.org

SAN FRANCISCO, United States, September 8, 2026 — Global UI/UX design agency Wavespace has unveiled ‘Beyond the Chatbox’, a design framework for building AI agent interfaces that replaces the traditional chatbot with generative UI. The framework provides a repeatable approach to designing agents that demonstrate their work, gain user trust, and maintain user control.

The Chatbox is not a layer on top of the process of an agent becoming adopted; it’s the process itself. The framework provides five practices for agent design: make the agent’s reasoning visible to the user so they can understand what it is doing and why, design for state, instead of showing the user what messages to respond to, show them what interface they need to use to complete a task, build explicit trust cues that expose confidence and sources, keep clear human approval and handoff points before the agent acts, and render the specific interface a task requires (form, table, set of controls, etc.) rather than returning everything as text.

These practices combine to help get agent products out of the one-chat-box-shipped tool. The framework responds to a widening gap between how fast AI agents are being deployed and how well users actually adopt them.

Gartner forecasts that 40% of enterprise applications will include task-specific AI agents by the end of 2026, up from less than 5% in 2025.

Meanwhile, Gartner estimates over 40% of agentic AI initiatives will be discontinued by the end of 2027, due to lack of business value and insufficient controls.

One of the factors that determines whether an agent is understood, trusted, and retained in production is interface design, according to Wavespace.

Wavespace describes Beyond the Chatbox as a method of design and not a product or platform. It is used in agent product design engagements and is designed to complement the team’s current model, data, and engineering decisions to communicate state, confidence, and control to the people who use the agent. The framework is based on the patterns the agency has created in AI product work with startups and enterprise teams.

Applied work on AI products illustrates the approach. Wavespace redesigned the Kodezi, an AI tool for developers, by focusing on more explicit feedback, clearer paths, and more robust system states.

The redesigned experience helped developers reach their first fix 34% sooner and increased use of the platform’s AI-assisted workflows by 4%; the refined product also supported Kodezi in closing a $1.8 million seed round. These are the categories of outcomes the framework is built to influence: faster comprehension, higher trust, and more consistent engagement with AI features.

“Most teams send an agent as a chat box and let users believe in it,” said Shahid Miah, Founder and CEO of Wavespace. “Trust does not come from the model alone.

It’s from an interface that displays what the agent is doing, where the agent’s answer came from, and where the person is still in control. That’s how we design beyond the Chatbox.

Wavespace built the foundation of various AI products, including copilots, autonomous agents, and AI capabilities within current software.

It is designed to be applied whether a team is building a new agent from the ground up or adding agentic capability to an established product, and it slots into the agency’s broader UI/UX, product design, and design-system work.

About Wavespace

Wavespace is a global UI/UX design agency that creates and delivers web, mobile, and SaaS products for startups and enterprise teams, specializing in SaaS, fintech, and AI products. The agency has completed over 550 projects, received over 250+ Clutch reviews with an average rating of 4.9 stars, and had 92% client satisfaction.

Wavespace works with venture-backed and enterprise clients, including HeyGen and Kodezi, Delve, and Persana AI, and maintains offices in San Francisco and Dubai.

MEDIA DETAILS

Media Relations
Wavespace – UI/UX Design Agency
media@wavespace.agency
https://www.wavespace.agency/

SAN FRANCISCO, CA — September 2026 — Spyra Verified, a Japanese beauty discovery platform, is expanding its community-driven approach to introducing Japanese skincare, hair care and beauty products to consumers in international markets, including the United States, Australia, Latin America and Africa.

The company’s model combines community events, product testing and direct consumer feedback to help determine which Japanese beauty products are introduced to wider audiences. Rather than relying exclusively on established popularity or influencer promotion, Spyra Verified uses consumer interaction and feedback as part of its product-selection process.

“Product discovery becomes more useful when consumers have an opportunity to experience products and share their perspectives before wider distribution,” said CEO and Founder Anni Ankola. “Our goal is to provide access to Japanese beauty products while giving communities a meaningful role in determining which products are relevant to them.”

Community Feedback Supports Product Selection

Spyra Verified’s community events allow participants to interact directly with products and discuss characteristics including texture, packaging, application, fragrance and overall experience.

Feedback gathered through these interactions can help the company determine which products to feature and how they should be introduced to consumers in different markets. The approach recognizes that beauty preferences can vary according to climate, routines, hair and skin characteristics, and local consumer expectations.

The company says this process is intended to complement, rather than replace, conventional beauty discovery channels. Consumer reviews and product-testing experiences provide additional perspectives that can help shoppers understand how products may fit into individual routines.

Introducing Japanese Beauty to International Consumers

Japanese beauty products can be difficult for international consumers to discover when products have limited availability outside Japan or have not developed significant awareness in overseas markets.

Spyra Verified focuses on introducing Japanese skincare, hair care and beauty products while providing information about their intended use, texture, format and role within Japanese beauty routines.

The company’s approach also emphasizes that product suitability is individual. Community participation and reviews are intended to provide additional perspectives rather than suggest that a particular product will produce identical results for every consumer.

Expanding Access Across New Markets

Spyra Verified is developing access to Japanese beauty products across markets in the United States, Australia, Latin America and Africa. In these markets, the company says its community-based process can help identify products that generate meaningful interest among local consumers.

Among the products introduced through its selection process is the True Tone Vitamin C Cream Mist, which Spyra says was brought to market following community product-selection activity.

The company has also held community product-testing events, including an event at Adobe in San Francisco, California, where participants were able to interact with selected beauty products. 

As Spyra Verified expands internationally, its stated focus is to combine product access with consumer feedback and education, giving local communities a role in the discovery and evaluation of Japanese beauty products.

About Spyra Verified

Spyra Verified is a Japanese beauty discovery platform focused on bringing Japanese skincare, hair care and beauty products to consumers in international markets. Its product-selection approach incorporates community events, product testing and consumer feedback to identify products for wider introduction. Learn more at spyraverified.com.

Media Contact

Organization: Spyra Beauty
Contact: Spyra Beauty Team
Email: contact@spyraverified.com
Website: https://spyraverified.com/